Zimbabwe has turned down a significant American healthcare agreement worth $367m (£272m) over five years due to Washington's request for sensitive data.
This rejection became public after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government representative later clarified that the US was requesting genetic material for research and commercial purposes but refused to share the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable task of winding down our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged continued talks to secure a agreement suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Background
This development follows a similar situation in neighbouring Kenya, where a high court suspended a related health funding agreement following legal challenges were filed about the safety of citizens' health data.
After returning to office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and responsibility.
According to reports, Sixteen nations in Africa have to date signed these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership could have provided extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy via American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, with no corresponding guarantee of access to any medical innovations – such as new medicines or tests – that might result from that provided information," he stated.
"Effectively, our nation would supply the raw materials for scientific discovery with no assurance that the final treatments would be available to our people should a future pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were undermining structures already established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This system is intended to ensure that when a country provides its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to further dialogue with our US partners on how subsequent collaboration could be designed in a way that respects the independence and interests of both nations."
Health Experts Response
A leading public health body stated it understood the official position, but suggested that negotiations need to persist since a large portion of the nation's HIV programmes relied on external financing.
"In cases where specific concerns arise, such as those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," the group added.
The situation underscores the ongoing tensions between accepting vital international aid and safeguarding a country's data in an increasingly interconnected world.